NeueHealth (NYSE:NEUE) - 주가, 뉴스 및 분석

NEUE 주식 개요

는 미국의 의료 소비자, 의료 서비스 제공자, 의료비 지불자를 위한 다양한 의료 서비스를 제공하는 헬스케어 회사입니다. 자세한 내용

NEUE 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	1/6
과거 실적	3/6
재무 상태	0/6
배당금	0/6

보상

주가수익률( 1.5 x)이 US 시장( 19 x)보다 낮습니다.

수익은 연간 11.08% 증가할 것으로 예상됩니다.

올해부터 흑자전환

위험 분석

마이너스 주주 지분

부채는 영업현금흐름으로 충분히 감당되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $42M )

NeueHealth, Inc. 경쟁사

Pacific Health Care Organization

OTCPK:PFHO

US$9.7m

Progyny

NasdaqGS:PGNY

US$1.2b

Daxor

NasdaqCM:DXR

US$43.6m

American Shared Hospital Services

NYSEAM:AMS

US$19.4m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 NeueHealth
과거 주가
현재 주가	US$4.94
52주 최고치	US$16.59
52주 최저치	US$4.66
베타	0.77
11개월 변경	-11.39%
3개월 변경 사항	-3.98%
1년 변경 사항	-34.13%
33년 변화	-98.39%
5년 변화	n/a
IPO 이후 변화	-99.63%

최근 뉴스 및 업데이트

Recent updates

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Oct 11

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Aug 13

Bright Health Group Takes Cost Actions To Effect Turnaround

Jul 21

Bright Health Group: Examining A Dumpster Fire

Jan 04

주주 수익률

	NEUE	US Healthcare	US 마켓
7D	-3.3%	-5.1%	-2.1%
1Y	-34.1%	3.0%	29.7%

수익률 대 산업: NEUE 지난 1년 동안 3 %를 반환한 US Healthcare 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: NEUE 지난 1년 동안 29.7 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is NEUE's price volatile compared to industry and market?
NEUE volatility
NEUE Average Weekly Movement	7.3%
Healthcare Industry Average Movement	6.9%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.1%

안정적인 주가: NEUE 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: NEUE 의 주간 변동성은 지난 1년 동안 14% 에서 7% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
2015	1,252	Mike Mikan	www.neuehealth.com

는 미국의 의료 소비자, 의료 서비스 제공자, 의료비 지불자를 대상으로 다양한 의료 서비스를 제공하는 헬스케어 회사입니다. 이 회사는 두 가지 부문으로 운영됩니다: 노이에케어와 노이에솔루션. 노이에케어 부문은 소유 및 제휴 클리닉을 통해 ACA 마켓플레이스, 메디케어, 메디케이드에 의료 서비스를 제공합니다.

NeueHealth, Inc. 기본 사항 요약

NeueHealth 의 수익과 매출은 시가총액과 어떻게 비교하나요?
NEUE 기본 통계
시가총액	US$41.51m
수익(TTM)	US$27.69m
수익(TTM)	US$996.89m

1.5x

P/E 비율

0.0x

P/S 비율

NEUE 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
NEUE 손익 계산서(TTM)
수익	US$996.89m
수익 비용	US$822.11m
총 이익	US$174.78m
기타 비용	US$147.09m
수익	US$27.69m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	3.36
총 마진	17.53%
순이익 마진	2.78%
부채/자본 비율	-38.5%

NEUE 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

NEUE 주식 개요

보상

위험 분석

NeueHealth, Inc. 경쟁사

OTCPK:PFHO

US$9.7m

NasdaqGS:PGNY

US$1.2b

NasdaqCM:DXR

US$43.6m

NYSEAM:AMS

US$19.4m

가격 내역 및 성능

최근 뉴스 및 업데이트

Third quarter 2024 earnings released: US$6.78 loss per share (vs US$72.52 loss in 3Q 2023)

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Insufficient new directors

Second quarter 2024 earnings released: US$6.42 loss per share (vs US$8.55 loss in 2Q 2023)

NeueHealth, Inc. Updates Earnings Guidance for the Year 2024

Recent updates

Third quarter 2024 earnings released: US$6.78 loss per share (vs US$72.52 loss in 3Q 2023)

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Insufficient new directors

Second quarter 2024 earnings released: US$6.42 loss per share (vs US$8.55 loss in 2Q 2023)

NeueHealth, Inc. Updates Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New major risk - Financial position

NeueHealth, Inc. announced that it has received $150 million in funding

New minor risk - Shareholder dilution

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$2.31 loss per share (vs US$9.04 loss in 1Q 2023)

NeueHealth, Inc. to Report Q1, 2024 Results on May 08, 2024

NeueHealth, Inc., Annual General Meeting, May 02, 2024

Vice Chairman recently sold US$59k worth of stock

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$70.72 loss per share (vs US$98.28 loss in FY 2022)

NeueHealth, Inc. Provides Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Third quarter 2023 earnings released: US$72.52 loss per share (vs US$40.11 loss in 3Q 2022)

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

New major risk - Revenue and earnings growth

Bright Health Group, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Bright Health Group, Inc. Announces Leaving of Jeff Cook as Chief Operating Officer, Effective October 13, 2023

Consensus EPS estimates upgraded to US$51.32 loss

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Revises Its Financial Outlook for 2023

Bright Health Group, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Price target increased by 47% to US$200

Florence Labs, Inc. acquired Zipnosis, Inc. from Bright Health Group, Inc. (NYSE:BHG).

Price target decreased by 14% to US$1.70

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group Announces Chief Financial Officer Changes

Vice Chairman recently sold US$158k worth of stock

Price target decreased by 24% to US$1.50

Consensus EPS estimates fall by 14%

Full year 2022 earnings released: US$1.23 loss per share (vs US$3.02 loss in FY 2021)

Bright Health Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Bright Health Group: Stock Price Has Been Too Heavily Beaten Down

Bright Health Group expects FY23 revenue to be below consensus

Independent Director recently bought US$248k worth of stock

Bright Health Group Receives Continued Listing Standard Notice from NYSE

Bright Health receives non-compliance notice from NYSE

Independent Lead Director recently bought US$294k worth of stock

Price target decreased to US$2.07

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2022

Bright Health Group reports Q3 mixed earnings; revises Fy22 guidance

Bright Health Group, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Bright Health Group, Inc. announced that it has received $175 million in funding from a group of investors

Bright Health Group, Inc. Provides Revenue Guidance for the Year 2023

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Provides Revenue Guidance for the Full Year 2022

Bright Health Group, Inc. to Report Q2, 2022 Results on Aug 10, 2022